New device zaps kidney and liver nerves to tame high blood pressure

NCT ID NCT06907147

Recruiting now Disease control Sponsor: Medtronic Vascular Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a device that uses radiofrequency energy to disrupt nerve signals in the kidney and liver arteries, aiming to lower blood pressure in people with uncontrolled hypertension. About 175 adults aged 18-80 with high blood pressure despite medication will be enrolled. The main goal is to see if the procedure is safe and reduces blood pressure over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Multi-Organ Denervation Gemini System (a device that uses radiofrequency energy to disrupt nerve signals in the kidney and liver arteries)
What this could lead to: If it works, this could offer a new, drug-free way to control high blood pressure and reduce the risk of heart and kidney problems.
What could go wrong: This is an early pilot study with only 175 people, so results may not apply to everyone. The procedure involves artery access and carries risks like bleeding or vessel damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder Chronic Disease chronic kidney disease chronic renal failure syndrome diabetes mellitus Disease Attributes hypertensive disorder kidney disorder kidney failure Pathologic Processes vascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOVASCULAR DISEASES CHRONIC KIDNEY DISEASES DIABETES MELLITUS HYPERTENSION VASCULAR DISEASES

Contacts and locations

Locations

BayCare Health System Mease Countryside Hospital
RECRUITING

Safety Harbor, Florida, 34695, United States
Baylor Heart & Vascular Hospital
RECRUITING

Dallas, Texas, 75226, United States
Beth Israel Deaconess Medical Center
RECRUITING

Boston, Massachusetts, 02215, United States
Henry Ford Providence Hospital
RECRUITING

Southfield, Michigan, 48075-4818, United States
Hippokration General Hospital
RECRUITING

Athens, 11527, Greece
North Mississippi Medical Center
RECRUITING

Tupelo, Mississippi, 38801-4934, United States
Orlando Health Heart & Vascular Institute
RECRUITING

Orlando, Florida, 32806, United States
Piedmont Heart Institute
RECRUITING

Atlanta, Georgia, 30309-1281, United States
Renown Regional Medical Center
RECRUITING

Reno, Nevada, 89502, United States
Royal Perth Hospital (Dobney Hypertension Centre)
RECRUITING

Perth, 6000, Australia
Stanford Hospital and Clinics
RECRUITING

Stanford, California, 94305, United States
UT Health East Texas
RECRUITING

Tyler, Texas, 75701, United States
University Hospital Basel
RECRUITING

Basel, 4031, Switzerland
University Hospital Erlangen
RECRUITING

Erlangen, 91054, Germany
University Hospital of Galway
RECRUITING

Galway, H91 YR71, Ireland
University of North Carolina (UNC) Memorial Hospital
RECRUITING

Chapel Hill, North Carolina, 27599, United States
Universität des Saarlandes
RECRUITING

Homburg, 66421, Germany
Virtua Our Lady of Lourdes Hospital
RECRUITING

Camden, New Jersey, 08103, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.